<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20160709028845N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2022-03-07</date_registration>
      <primary_sponsor>Ahvaz University of Medical Sciences</primary_sponsor>
      <public_title>The effect of black seed on irritable bowel syndrome</public_title>
      <acronym></acronym>
      <scientific_title>Evaluation of total black seed (nigella sativa) extract efficacy in patients with irritable bowel syndrome</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2022-02-20</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>160</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/61056</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: Randomization is block randomization with block with sizes of two, four and six. We will use https://www.sealedenvelope.com for generating random sequences. This software will generate control and comparator groups and will generate unique codes for every participant. Participants will enroll according to the order of their entrance into the study. They will receive an opaque envelope that the unique code is on it and medicine is in it (concealment), Blinding description: Study participants as patients in the two study groups, researchers and physicians under their supervision. are kept blind.For blinding patients, the drug and placebo are provided to patients in similar containers, which are only mentioned in the title of the research project and serial number. At the end of the study, the serial is converted to groups A and B in Excel software. Statistical analysis then determines which group of drugs or placebo.</study_design>
      <phase>2-3</phase>
      <hc_freetext>irritable bowel syndrome.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: Patients with irritable bowel syndrome are taking 500 mg of black seed extract capsules every 12 hours during the study. Extraction and preparation of capsules is performed under the supervision of a pharmacist in Ahvaz Jundishapur School of Medical Sciences. The process of receiving black seed capsules is up to three months. Intervention 2: Control group: Patients with irritable bowel syndrome who take starch capsules as a placebo every 12 hours during the study. Extraction and preparation of capsules is done under the supervision of a refereeing specialist in Ahvaz Jundishapur School of Medical Sciences. The process of receiving black seed capsules is up to three months.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
All data in the form of typed files and the names of distorted patients are presented north of the questionnaires.

When:
Access period starts 6 months after the results are published

To whom:
Researchers working in academic and scientific institutions

Conditions:
After obtaining a permission from the Vice Chancellor for Research of Ahvaz University

Where to obtain:
Vice Chancellor for Research of Ahvaz University

How to obtain:
By sending an email and a complete introduction and the reason for the need to receive information, if the request for documents is appropriate, it will be sent via email.

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Nima Bakhtiarri</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No 4, 4th east street, Kianpars, Ahvaz</address>
        <city>Ahvaz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>6122334678</zip>
        <telephone>+98 61 3392 9324</telephone>
        <email>bakhtiari.n@ajums.ac.ir</email>
        <affiliation>Ahvaz University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Nima Bakhtiarri</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No 4, 4th east street, Kianpars, Ahvaz</address>
        <city>Ahvaz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>6133224678</zip>
        <telephone>+98 61 3392 9324</telephone>
        <email>bakhtiari.n@ajums.ac.ir</email>
        <affiliation>Ahvaz University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Diagnosis of Irritable Bowel Syndrome Based on Roma IV Diagnosis Criteria.
People aged 18 to 50 years and if they are over 50 years old, colonoscopy should be screened to make sure there are no other diseases and malignancies.
No malignancies (carcinoid and colorectal tumors), celiac disease, diverticulitis, gastrointestinal infections, hyper and hypothyroidism, lactose intolerance, IBD, and ischemic colitis
No previous use of drugs, calcium channel blockers and antidepressants</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>50 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Having a history of allergy to black seed compounds
Dissatisfaction with attending the study
Pregnancy</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>K58</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Irritable bowel syndrome</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Placebo</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: Patients with irritable bowel syndrome are taking 500 mg of black seed extract capsules every 12 hours during the study. Extraction and preparation of capsules is performed under the supervision of a pharmacist in Ahvaz Jundishapur School of Medical Sciences. The process of receiving black seed capsules is up to three months.</i_keyword>
      <i_keyword>Control group: Patients with irritable bowel syndrome who take starch capsules as a placebo every 12 hours during the study. Extraction and preparation of capsules is done under the supervision of a refereeing specialist in Ahvaz Jundishapur School of Medical Sciences. The process of receiving black seed capsules is up to three months.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Severity of abdominal pain,. Timepoint: every two weeks for three consecutive months. Method of measurement: Irritable bowel syndrome severity questionnaire using Visual Analogue Scale.</prim_outcome>
      <prim_outcome>Severity of abdominal distension. Timepoint: every two weeks for three consecutive months. Method of measurement: Irritable bowel syndrome severity questionnaire using Visual Analogue Scale.</prim_outcome>
      <prim_outcome>Satisfaction with defecation habit. Timepoint: every two weeks for three consecutive months. Method of measurement: Irritable bowel syndrome severity questionnaire using Visual Analogue Scale.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Quality of life in patients with irritable bowel syndrome. Timepoint: At the beginning of the study and every month for three consecutive months. Method of measurement: world health organization quality of life questioner (brief form).</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Ahvaz University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2022-01-09</approval_date>
        <contact_name>Ethics committee of Ahvaz Jondishapur University of Medical Sciences</contact_name>
        <contact_address>Azadegan St. (24 meters) Imam Khomeini Educational and Medical Center Ahwaz Khouzestan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
